High performance of F-fluorodeoxyglucose positron emission tomography and contrast-enhanced CT in a rapid outpatient diagnostic program for patients with suspected lung cancer

Respiration. 2014;87(1):32-7. doi: 10.1159/000347096. Epub 2013 Apr 16.

Abstract

Background: The diagnostic evaluation of patients presenting with possible lung cancer is often complex and time consuming. A rapid outpatient diagnostic program (RODP) including (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and contrast-enhanced computed tomography (CT) as a routine diagnostic tool may improve timeliness, however the diagnostic performance of such a combined approach of RODP remains unclear.

Objectives: We evaluated timeliness of care and diagnostic performance of FDG-PET and contrast-enhanced CT (FDG-PET/CT) in an RODP for all patients referred with a chest X-ray suspicious of lung cancer.

Methods: Charts of patients referred to the 2-day RODP of our tertiary care university clinic after an abnormal chest X-ray between 1999 and 2009 were reviewed. Between 1999 and 2005 co-registered FDG-PET and CT imaging took place; from September 2005 onwards, a hybrid system was used. We analyzed timeliness of care and diagnostic performance of FDG-PET/CT to differentiate malignant from benign lesions.

Results: In 386 patients available for analysis, 260 were diagnosed with lung cancer and 23 had another type of malignancy; in 78 patients benign disease was confirmed, and in another 45 the diagnosis was not pathologically confirmed but a median 24.5-month follow-up confirmed a benign outcome. Sensitivity, specificity, negative and positive predictive values and accuracy of FDG-PET/CT to differentiate lung cancer from benign disease were 97.7, 60.2, 92.5, 84.0 and 85.8%, respectively. Lung cancer patients had a median referral, diagnostic and therapeutic delay of 7, 2 and 19 days, respectively.

Conclusions: FDG-PET/CT in an RODP setting for suspected lung cancer has high performance in detecting cancer and facilitates timely care.

MeSH terms

  • Aged
  • Ambulatory Care
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / diagnostic imaging
  • Cohort Studies
  • Contrast Media
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / diagnostic imaging
  • Male
  • Mesothelioma / diagnosis*
  • Mesothelioma / diagnostic imaging
  • Mesothelioma, Malignant
  • Middle Aged
  • Multimodal Imaging*
  • Positron-Emission Tomography*
  • Radiopharmaceuticals
  • Retrospective Studies
  • Sensitivity and Specificity
  • Small Cell Lung Carcinoma / diagnosis*
  • Small Cell Lung Carcinoma / diagnostic imaging
  • Tomography, X-Ray Computed*

Substances

  • Contrast Media
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18